Loading stock data…
Immuneering Corporation (IMRX)
$4.78-0.04 (-0.83%)
Market ClosedLast close Sep 8
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immuneering Corporation in the Healthcare sector is trading at $4.78 with a market capitalization of $309M. Wall Street consensus targets $17.17 (6 analysts), implying a +259.1% move over the next 12 months. The stock is currently near its 52-week low of $3.86, remaining 9.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +259.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.00M↓ | -$15.33M↓ | -$13.75M↑ | -$15.38M↓ | -$14.76M |
| Net Income | -$17.27M↓ | -$13.46M↓ | -$11.58M↑ | -$14.96M↓ | -$14.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$309.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.03%
Volume
Today's trading volume
1.03M
Recent News
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Immuneering...